Wire · operational-macro
Labcorp to buy BioReference assets for up to $872M
◆ Sectors
Diagnostics
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 16 October 2026 · Fusion42 review
Labcorp is acquiring BioReference assets for up to $872 million, expanding its specialty testing in women’s health and adding a blood test that predicts aggressive prostate cancer before biopsy.
This Wire brief sits within Fusion42's coverage of Diagnostics.
◆ ◆ The Wire takeaway
Labcorp’s acquisition signals tighter concentration in specialty diagnostics, creating openings for smaller labs to fill gaps left by consolidation in women’s health and prostate cancer testing.
◆ Coverage
1 source · 16 Oct 2026
◆ Related on Wire
◆ Topics
Diagnosticshealthcare-malabcorpbioreferencediagnosticsspecialty-testing